.jpeg)
2026-07-30 06:32:34
A systematic review of the highly selective MET inhibitor capmatinib in MET exon 14 skipping mutation non-small cell lung cancer, covering efficacy data, horizontal comparison with tepotinib, first-line and later-line monotherapy strategies, and emerging combination therapy directions.
2026-07-30 05:15:44
A systematic review of the oral TPO-RA avatrombopag covering its mechanism of action, three approved indications, short-course and long-term maintenance regimens, and comprehensive efficacy and safety comparisons with eltrombopag and hetrombopag to support individualized precision treatment.
2026-07-30 04:19:01
A comprehensive analysis of the highly selective RET inhibitor pralsetinib, covering discontinuation criteria, comparative efficacy with selpercatinib, and first-line and later-line treatment strategies for RET fusion-positive solid tumors.
2026-07-30 03:13:41
A comprehensive analysis of venetoclax, the world's first oral BCL-2 inhibitor, covering its pharmacological mechanism, clinical applications in CLL and AML, and strategic considerations for choosing between originator and generic formulations.
2026-07-30 03:05:05
A comprehensive overview of dabrafenib's approved indications, monotherapy versus combination with trametinib, and comparative analysis with vemurafenib and encorafenib for BRAF V600-mutant solid tumors.
2026-07-29 06:19:15
Elagolix is an oral GnRH receptor antagonist used to treat endometriosis-associated pain. This article reviews its common side effects, bone density impact, emotional changes, and safety considerations to help patients understand the medication comprehensively.
2026-07-29 06:14:14
Hetrombopag and avatrombopag are both oral thrombopoietin receptor agonists (TPO-RAs) used to treat thrombocytopenia. This article systematically compares their mechanisms of action, approved indications, dosing regimens, and safety warnings to support informed clinical decision-making.
2026-07-29 06:08:41
Lytenava (bevacizumab-vikg) is the first ophthalmic bevacizumab formulation approved by the FDA, developed by Outlook Therapeutics for the treatment of wet age-related macular degeneration (wet AMD). It received FDA approval on July 24, 2026.
2026-07-28 05:34:00
On July 24, 2026, Outlook Therapeutics announced FDA approval of Lytenava (bevacizumab-vikg) for neovascular age-related macular degeneration (wet AMD) — the first bevacizumab formulation purpose-built for intravitreal injection.
2026-07-28 02:31:53
On July 24, 2026, the U.S. FDA approved Otsuka Pharmaceutical's extended-release capsule Simtriyo (centanafadine) for the treatment of ADHD in patients aged 6 years and older. As the first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI), this once-daily oral medication simultaneously modulates three neurotransmitter pathways, offering a new long-acting option for patients with comorbid anxiety or intolerance to traditional stimulants.
2026-07-24 07:46:29
Developed by Merck, Lipfendra (enlicitide) is the first FDA-approved oral PCSK9 inhibitor, offering a once-daily tablet that significantly reduces LDL-C levels in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
2026-07-23 06:02:51
Orforglipron (brand name Foundayo) is the first approved oral small-molecule non-peptide GLP-1 receptor agonist for long-term weight management in adults with obesity or overweight, taken once daily without food or water restrictions.
